Exploring innovative business models and development strategies to meet evolving R&D challenges

Dr. Yuan Xu, Vice President and Head of Biotherapeutics Development, Novartis, United States will be speaking on the above topic at Drug Discovery World Asia 2012, part of a series of conferences at 5th Annual BioPharma Asia Convention 2012.

Dr Yuan Xu is currently the Vice President and Head of Biotherapeutics Development Unit at Novartis, GNF/NIBR. Yuan joined Novartis in 2008. Previously, she held the following positions: 2008-2011: Novartis, Global Head and Vice President of Process Sciences & Production and Basel Site Head for Novartis Biologics. 2006-2008: Amgen, first as Global Head leading Corporate Process and Clinical Operations then as Global Head leading Global Operations Strategy. 2004-2006: Chiron/Novartis, as Senior Director of Global Regulatory Affairs, as well as Global Program Head. 2003-2004: GlaxoSmithKline, Senior Group Director of Worldwide Biopharm Development 1995-2003: Genentech, held roles of increasing responsibility in Process Sciences, including Head of Pilot Plant Operations. Dr Yuan has extensive scientific/technical expertise and development/regulatory experience with multiple successful biotech products: Activase, Pulmozyme, Rituxan, Herceptin, TNKase, Xolair, Raptiva, Avastin, Lucentis, Bexxar, Bacaplemin, Proleukin, Epogen, Enbrel, Prolia and Ilaris. Dr Yuan performed Postdoc training in Molecular Virology and Gene Therapy from University of California at San Diego Medical School. Dr Yuan has a Ph.D. in Protein Biochemistry from the University of Maryland at College Park and a B.S. in Biochemistry and Molecular Biology from Nanjing University in China.

If you woud like to know more, join us at BioPharma Asia Convention 2012 to gain valuable insights from more than 200 experts. Contact us now for more details!